Surgery Deemed Fitting for Some Stage IIIB NSCLC Patients

This article originally appeared here.
Share this content:
Surgery Deemed Fitting for Some Stage IIIB NSCLC Patients
Surgery Deemed Fitting for Some Stage IIIB NSCLC Patients

(HealthDay News) -- Patients with stage IIIB non-small-cell lung cancer (NSCLC) could live longer by undergoing surgical resection, instead of receiving only chemotherapy and radiation, according to research published in the June issue of The Annals of Thoracic Surgery.

Varun Puri, M.D., an assistant professor of surgery in the division of cardiothoracic surgery at the Washington University School of Medicine in St. Louis, and colleagues evaluated data from the National Cancer Database on 9,173 patients with stage IIIB NSCLC who underwent a combination of treatments between 1998 and 2010. Of these patients, 7,459 were treated with chemotherapy and radiation only, while 1,714 also had surgery in addition to those treatments.

The researchers found that average overall survival in the surgical group was nearly 26 months, compared to just over 16 months in the chemo-radiation group.

"We think our study reignites a question that was initially asked in the 1980s and 1990s but has become more or less dormant in lung cancer circles," Puri told HealthDay. According to Puri, the take-home message from the study is that "we should not consider all stage IIIB NSCLC patients as being eligible for only chemo-radiation therapy. An experienced thoracic surgeon should evaluate these patients and decide [if surgery is also an option] on a case-by-case basis."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Vit D Independently, Inversely Tied to Cholesterol in Children

Vit D Independently, Inversely Tied to Cholesterol in ...

Gene variants do not modify the associations of 25(OH)D with lipids

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Lower degree of susceptibility to ibalizumab for nine of 10 patients with virology failure, rebound

Weight Gain After Quitting Smoking May Up T2DM Risk

Weight Gain After Quitting Smoking May Up T2DM ...

But temporary increase in type 2 diabetes risk does not attenuate benefits on total, CVD mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »